NASDAQ:ZIVO ZIVO Bioscience (ZIVO) Stock Price, News & Analysis $13.00 0.00 (0.00%) As of 09/12/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About ZIVO Bioscience Stock (NASDAQ:ZIVO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ZIVO Bioscience alerts:Sign Up Key Stats Today's Range$13.00▼$13.0050-Day Range$9.97▼$19.0152-Week Range$9.97▼$22.15Volume54 shsAverage Volume1,095 shsMarket Capitalization$49.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ZIVO Bioscience is a clinical-stage biotechnology company focused on developing precision live biotherapeutics to prevent and treat gastrointestinal infections in both animal and human health markets. The company applies synthetic biology, microbiology and fermentation technologies to engineer proprietary bacterial strains that produce targeted lactic acid and antimicrobial compounds. Its pipeline includes ZB-01, an orally administered therapy for recurrent Clostridioides difficile infections in humans, and ZB-02, a feed-additive candidate aimed at reducing Salmonella colonization in poultry. Founded in 2016 and headquartered in Carlsbad, California, ZIVO Bioscience leverages exclusive licensing agreements with academic institutions to advance its lead programs through preclinical and early clinical development. The company’s animal health platform is designed to offer an antibiotic‐free approach to controlling foodborne pathogens, while its human health efforts target high-unmet-need gastrointestinal diseases where current therapies fall short or carry significant safety risks. ZIVO’s proprietary fermentation processes are scalable and designed to meet regulatory standards for both veterinary and human therapeutics. The company collaborates with contract development and manufacturing organizations (CDMOs) to produce its live bacterial formulations under Good Manufacturing Practices (GMP). These partnerships aim to accelerate the transition of ZIVO’s pipeline assets from research to first-in-human trials and commercial supply. Under the leadership of CEO Jon Bany, ZIVO Bioscience continues to build a multidisciplinary team of experts in microbiology, immunology and process development. The company’s strategic focus on dual animal and human health applications reflects a growing industry emphasis on microbiome-based solutions that improve public health outcomes while addressing regulatory pressures to reduce antibiotic use in agriculture.AI Generated. May Contain Errors. Read More ZIVO Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreZIVO MarketRank™: ZIVO Bioscience scored higher than 7% of companies evaluated by MarketBeat, and ranked 944th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ZIVO Bioscience. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ZIVO Bioscience is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ZIVO Bioscience is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ZIVO Bioscience's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.67% of the float of ZIVO Bioscience has been sold short.Short Interest Ratio / Days to CoverZIVO Bioscience has a short interest ratio ("days to cover") of 24.3, which indicates bearish sentiment.Change versus previous monthShort interest in ZIVO Bioscience has recently decreased by 1.82%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZIVO Bioscience does not currently pay a dividend.Dividend GrowthZIVO Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.67% of the float of ZIVO Bioscience has been sold short.Short Interest Ratio / Days to CoverZIVO Bioscience has a short interest ratio ("days to cover") of 24.3, which indicates bearish sentiment.Change versus previous monthShort interest in ZIVO Bioscience has recently decreased by 1.82%, indicating that investor sentiment is improving. News and Social Media2.3 / 5News Sentiment0.22 News SentimentZIVO Bioscience has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ZIVO Bioscience this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added ZIVO Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ZIVO Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders48.90% of the stock of ZIVO Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.83% of the stock of ZIVO Bioscience is held by institutions.Read more about ZIVO Bioscience's insider trading history. Receive ZIVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZIVO Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZIVO Stock News HeadlinesZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic BusinessesSeptember 10 at 8:30 AM | businesswire.comAIM ImmunoTech (NYSE:AIM) vs. ZIVO Bioscience (NASDAQ:ZIVO) Head to Head ReviewSeptember 8, 2025 | americanbankingnews.comReagan’s former tech advisor sharing bombshell announcementGeorge Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.September 13 at 2:00 AM | Banyan Hill Publishing (Ad)ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in PoultryJune 20, 2025 | businesswire.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 7, 2025 | finance.yahoo.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 6, 2025 | businesswire.comZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in PoultryFebruary 6, 2025 | businesswire.comZivo Bioscience issues new shares, raises $1.5 millionJanuary 28, 2025 | msn.comSee More Headlines ZIVO Stock Analysis - Frequently Asked Questions How have ZIVO shares performed this year? ZIVO Bioscience's stock was trading at $21.50 at the start of the year. Since then, ZIVO stock has decreased by 39.5% and is now trading at $13.00. How were ZIVO Bioscience's earnings last quarter? ZIVO Bioscience, Inc. (NASDAQ:ZIVO) issued its earnings results on Monday, May, 11th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.02 million for the quarter. When did ZIVO Bioscience's stock split? ZIVO Bioscience's stock reverse split on the morning of Friday, October 27th 2023.The 1-6 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. How do I buy shares of ZIVO Bioscience? Shares of ZIVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ZIVO Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that ZIVO Bioscience investors own include Canopy Growth (CGC), Meta Platforms (META), OPKO Health (OPK), Johnson & Johnson (JNJ), ACADIA Pharmaceuticals (ACAD), ARAVIVE (ARAV) and Alibaba Group (BABA). Company Calendar Last Earnings5/11/2020Today9/13/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZIVO Previous SymbolOTCMKTS:HEPI CIK1101026 Webwww.zivobioscience.com Phone(248) 452-9866FaxN/AEmployees10Year Founded1999Profitability EPS (Trailing Twelve Months)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.78 million Net MarginsN/A Pretax Margin-17,113.75% Return on EquityN/A Return on Assets-2,240.92% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.17 Sales & Book Value Annual Sales$15.85 thousand Price / Sales3,130.66 Cash FlowN/A Price / Cash FlowN/A Book Value($0.81) per share Price / Book-16.05Miscellaneous Outstanding Shares3,817,000Free Float2,911,000Market Cap$49.62 million OptionableNot Optionable BetaN/A Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ZIVO) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZIVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.